KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Asset Writedowns and Impairment (2021 - 2025)

Historic Asset Writedowns and Impairment for ClearPoint Neuro (CLPT) over the last 5 years, with Q1 2025 value amounting to $217000.0.

  • ClearPoint Neuro's Asset Writedowns and Impairment rose 24863.01% to $217000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $428000.0, marking a year-over-year increase of 38157.89%. This contributed to the annual value of -$296000.0 for FY2024, which is 12352.94% down from last year.
  • As of Q1 2025, ClearPoint Neuro's Asset Writedowns and Impairment stood at $217000.0, which was up 24863.01% from $211000.0 recorded in Q4 2024.
  • Over the past 5 years, ClearPoint Neuro's Asset Writedowns and Impairment peaked at $449000.0 during Q3 2023, and registered a low of -$361000.0 during Q2 2024.
  • Its 5-year average for Asset Writedowns and Impairment is $79000.0, with a median of $64500.0 in 2021.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first crashed by 213333.33% in 2022, then soared by 152000.0% in 2023.
  • Over the past 5 years, ClearPoint Neuro's Asset Writedowns and Impairment (Quarter) stood at $32000.0 in 2021, then crashed by 178.12% to -$25000.0 in 2022, then soared by 1520.0% to $355000.0 in 2023, then crashed by 40.56% to $211000.0 in 2024, then grew by 2.84% to $217000.0 in 2025.
  • Its last three reported values are $217000.0 in Q1 2025, $211000.0 for Q4 2024, and -$361000.0 during Q2 2024.